| 1. | https://www.klug-entscheiden.com/einfuehrung/konsensus-kommission-ke (last accessed on XX Xxxxxxx XXXX). |
| 2. | https://www.klug-entscheiden.com/empfehlungen/uebersicht (last accessed on XX Xxxxxxx XXXX). |
| 3. | Bhandari S, Mehta S, Khwaja A, et al.: Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease. N Engl J Med 2022; 387: 2021–32. |
| 4. | Fu EL, Evans M, Clase CM, et al.: Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes: A Nationwide Study. J Am Soc Nephrol 2021; 32: 424– 35. |
| 5. | Qiao Y, Shin JI, Chen TK, et al.: Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate. JAMA Intern Med 2020; 180: 718–26. |
| 6. | European Antimicrobial Resistance Collaborators. The burden of bacterial antimicrobial resistance in the WHO European region in 2019: a cross-country systematic analysis. Lancet Public Health 2022; 7: e897–913. |
| 7. | Chong Y, Shimoda S, Miyake N, et al.: Incomplete recovery of the fecal flora of hematological patients with neutropenia and repeated fluoroquinolone prophylaxis. Infect Drug Resist 2017; 10: 193–9. |
| 8. | Vehreschild MJ, Hamprecht A, Peterson L, et al.: A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. J Antimicrob Chemother 2014; 69: 3387–92. |
| 9. | Classen AY, Henze L, von Lilienfeld-Toal M, et al.: Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO). Ann Hematol 2021; 100: 1603–20. |
| 10. | Thorpe A, Sirota M, Juanchich M, et al.: Action bias in the public’s clinically inappropriate expectations for antibiotics. J Exp Psychol Appl 2020; 26: 422–31. |
| 11. | Cometta A, Kern WV, De Bock R, et al.: Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 2003; 37: 382–9. |
| 12. | Wu CW, Wu JY, Chen CK, et al.: Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diagnosis of severe infection in patients with febrile neutropenia? A systematic review and meta-analysis. Supportive Care Cancer 2015; 23: 2863–72. |
| 13. | Heinz WJ, Buchheidt D, Christopeit M, et al.: Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 2017; 96: 1775–92. |
| 14. | Hansson C, Hoborn J, Möller A, et al.: The microbial flora in venous leg ulcers without clinical signs of infection. Repeated culture using a validated standardised microbiological technique. Acta Dermato-Venereologica 1995; 75: 24–30. |
| 15. | Matkoski C, Sharp SE, Kiska DL: Evaluation of the Q score and Q234 systems for cost-effective and clinically relevant interpretation of wound cultures. J Clin Microbiol 2006; 44: 1869–72. |
| 16. | Chakraborti C, Le C, Yanofsky A: Sensitivity of superficial cultures in lower extremity wounds. J Hosp Med 2010; 5: 415–20. |
| 17. | Gardner SE, Haleem A, Jao YL, et al.: Cultures of diabetic foot ulcers without clinical signs of infection do not predict outcomes. Diabetes Care 2014; 37: 2693–701. |
| 18. | Lipsky BA, Senneville É, Abbas ZG, et al.: International Working Group on the Diabetic Foot (IWGDF). Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diabetes Metab Res Rev 2020; 36 (Suppl 1): e3280. |
| 19. | Marchand-Senécal X, Brasg I, Kozak R, et al.: Impact of Rejection of Low-Quality Wound Swabs on Antimicrobial Prescribing: A Controlled Before-After Study. Open Forum Infect Dis 2020; 8: ofaa609. |
| 20. | Camilleri Attard F, Gatt A, Formosa C: Superficial tissue swabs versus deep tissue samples in the detection of microbiological profile of infected diabetic foot ulcerations. Int J Low Extr Wounds 2021; DOI 10.1177/15347346211053481. |
| 21. | Hindricks G, Potpara T, Dagres N, et al.: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2021; 42: 373–498. |
| 22. | Eckardt L, Wolfes J, Frommeyer G: Benefits of early rhythm control of atrial fibrillation. Trends Cardiovasc Med 2023; 11: S1050–1738(23)00041–5. |
| 23. | Kirchhof P, Camm AJ, Goette A, et al.: Early rhythm-control therapy in patients with atrial fibrillation. N Eng J Med 2020; 383: 1305–16. |
| 24. | Willems S, Bororf K, Brandes A, et al.: Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. Eur Heart J 2022; 43: 1219–30. |
| 25. | Eckardt L, Sehner S, Sulig A, et al.: Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST-AFNET 4 trial. Eur Heart J 2022; 43: 4127–414. |
| 26. | Andrade JG, Wells GA, Deyell MW, et al.: Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation. N Eng J Med 2021; 384: 305–15. |
| 27. | Wazni OM, Dandamudi G, Sood N, et al.: Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation. N Eng J Med 2021; 384: 316–24. |
| 28. | Borch JE, Andersen KE, Bindslev-Jensen C: The prevalence of suspected and challenge-verified penicillin allergy in a university hospital population. Basic Clin Pharmacol Toxicol 2006; 98: 357–62. |
| 29. | Shenoy ES, Macy E, Rowe T, et al.: Evaluation and Management of Penicillin Allergy: A Review. JAMA 2019; 321: 188–99. |
| 30. | Blumenthal KG, Peter JG, Trubiano JA, et al.: Antibiotic allergy. Lancet 2019; 393: 183–98. |
| 31. | West RM, Smith CJ, Pavitt SH, et al.: ‘Warning: allergic to penicillin’: association between penicillin allergy status in 2.3 million NHS general practice electronic health records, antibiotic pre- scribing and health outcomes. J Antimicrob Chemother 2019; 74: 2075–82. |
| 32. | Lee CE, Zembower TR, Fotis MA, et al.: The incidence of antimicrobial allergies in hospitalized patients: implications regarding prescribing patterns and emerging bacterial resistance. Arch Intern Med 2000; 160: 2819–22. |
| 33. | Blumenthal KG, Kuper K, Schulz LT, et al.: Association Between Penicillin Allergy Documentation and Antibiotic Use. JAMA Intern Med 2020; 180: 1120–2. |
| 34. | Blumenthal KG, Lu N, Zhang Y, et al.: Risk of meticillin resistant Staphylococcus aureus and Clostridium difficile in patients with a documented penicillin allergy: population based matched cohort study. BMJ 2018; 361: k2400. |
| 35. | Macy E, Contreras R: Health care use and serious infection prevalence associated with penicillin „allergy“ in hospitalized patients: A cohort study. J Allergy Clin Immunol 2014; 133: 790–6. |
| 36. | Perez-Encinas M, Lorenzo-Martínez S, Losa-García JE, et al.: Impact of Penicillin Allergy Label on Length of Stay and Mortality in Hospitalized Patients through a Clinical Administrative National Dataset. Int Arch Allergy Immunol 2022; 183: 498–506. |
| 37. | Huang KG, Cluzet V, Hamilton K, et al.: The Impact of Reported Beta-Lactam Allergy in Hospitalized Patients With Hematologic Malignancies Requiring Antibiotics. Clin Infect Dis 2018; 67: 27–33. |
| 38. | Kaminsky LW, Ghahramani A, Hussein R, et al.: Penicillin Allergy Label Is Associated With Worse Clinical Outcomes in Bacterial Pneumonia. J Allergy Clin Immunol Pract 2022;10: 3262–9. |
| 39. | S3-Leitlinie Strategien zur Sicherung rationaler Antibiotika-Anwendung im Krankenhaus.AWMF-Registernummer 092/001 – update 2018. https://register.awmf.org/de/leitlinien/detail/092–001 (last accessed on 26 April 2023). |
| 40. | Trubiano JA, Vogrin S, Chua KYL, et al.: Development and Validation of a Penicillin Allergy Clinical Decision Rule. JAMA Internal Medicine 2020;180: 745–52. |
| 41. | Copaescu AM, Vogrin S, James F, et al.: Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy: The PALACE Randomized Clinical Trial. JAMA Intern Med 2023; 183: 944–52. |
| 42. | Piotin A, Godet J, Trubiano A, et al.: Predictive factors of amoxicillin immediate hypersensitivity and validation of PEN-FAST clinical decision rule. Ann Allergy Asthma Immunol 2022; 128: 27–32. |
| 43. | Koch T, Leubner H, Brehm T, Witte J: Penicillinallergie: Sicher und effektiv ausschließen. Dtsch Arztebl 2023; 120: A-822/B-699. |
| 44. | Rinella ME, Lazarus JV, Ratziu V, et al.: A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023; 78: 1966–86. |
| 45. | Ward ZJ, Bleich SN, Cradock AL, et al.: Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. N Engl J Med 2019; 381: 2440–50. |
| 46. | Estes C, Razavi H, Loomba R, et al.: Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018; 67: 123–33. |
| 47. | Huang DQ, Wilson LA, Behling C, et al.: Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study. Gastroenterology 2023; 165: 463–72.e5. |
| 48. | Koutoukidis DA, Koshiaris C, Henry JA, et al.: The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: A systematic review and meta-analysis. Metabolism 2021; 115: 1544–55. |
| 49. | Roeb E, Canbay A, Bantel H, et al.: Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) April 2022 – AWMF-Registernummer: 021-025. |
| 50. | Hannah WN Jr, Harrison SA: Effect of Weight Loss, Diet, Exercise, and Bariatric Surgery on Nonalcoholic Fatty Liver Disease. Clin Liver Dis 2016; 20: 339–50. |
| 51. | Hall KD, Ayuketah A, Brychta R, et al.: Ultra-Processed Diets Cause Excess Calorie Intake and Weight Gain: An Inpatient Randomized Controlled Trial of Ad Libitum Food Intake. Cell Metab 2019; 30: 67–77.e3. Erratum in: Cell Metab 2019; 30: 226 and Cell Metab 2020; 32: 690. |
| 52. | Vancells Lujan P, Viñas Esmel E, Sacanella Meseguer E: Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development. Nutrients 2021; 13: 1442. |
| 53. | Malik VS, Hu FB: The role of sugar-sweetened beverages in the global epidemics of obesity and chronic diseases. Nat Rev Endocrinol 2022; 18: 205–18. |
| 54. | Newsome PN, Buchholtz K, Cusi K, et al.: A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med 2021; 384: 1113–24. |
| 55. | Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al.: Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology 2015; 149: 367–78.e5. |
| 56. | Promrat K, Kleiner DE, Niemeier HM, et al.: Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51: 121–129. |
| 57. | Keating SE, Hackett DA, George J, et al.: Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012; 57: 157–66. |
| 58. | Johnson NA, Sachinwalla T, Walton DW, et al.: Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009; 50: 1105–12. |
| 59. | Hashida R, Kawaguchi T, Bekki M, et al.: Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. J Hepatol 2017; 66: 142–52. |
| 60. | Fernández T, Viñuela M, Vidal C, et al.: Lifestyle changes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. PLoS One 2022; 17: e0263931. |
| 61. | Verrastro O, Panunzi S, Castagneto-Gissey L, et al.: Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet 2023; 401: 1786–97. |
Klug entscheiden in der Gastroenterologie
Literaturnachweise 2024
Literaturnachweise 2023
| 1. | Klug entscheiden – Eine Initiative der Deutschen Gesellschaft für Innere Medizin (DGIM). Deutsches Ärzteblatt 2021; 118: Sammelband April 2021. https://www.klug-entscheiden.com/fileadmin/user_upload/2021_Sammelband_Klug_entscheiden_Web_final.pdf (last accessed 13 April 2023). |
| 2. | https://dgim.de/veroeffentlichungen/klug-entscheiden/ (last accessed 13 April 2023). |
| 3. | Singh P, Arora A, Strand TA, et al.: Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2018; 16: 823–36 CrossRef MEDLINE |
| 4. | Palmieri B, Vadala M, Laurino C: Gluten-free diet in non-celiac patients: beliefs, truths, advantages and disadvantages. Minerva Gastroenterol Dietol 2019; 65: 153–62. CrossRef MEDLINE |
| 5. | Melini V, Melini F: Gluten-Free Diet: Gaps and Needs for a Healthier Diet. Nutrients 2019; 11: 170. CrossRef MEDLINE PubMed Central |
| 6. | Leonard MM, Sapone A, Catassi C, et al.: Celiac Disease and Nonceliac Gluten Sensitivity: A Review. JAMA 2017; 318: 647–56. CrossRef MEDLINE |
| 7. | Welstead L: The Gluten-Free Diet in the 3rd Millennium: Rules, Risks and Opportunities. Diseases 2015; 3: 136–49. CrossRef MEDLINE PubMed Central |
| 8. | Felber J, Bläker H, Fischbach W, et al.: Aktualisierte S2k-Leitlinie Zöliakie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol 2022; 60: 790–856. CrossRef MEDLINE |
| 9. | Castellsague J, Riera-Guardia N, Calingaert B, et al.: Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012; 35: 1127–46. CrossRef MEDLINE PubMed Central |
| 10. | Yeomans ND, Lanas AI, Talley NJ, et al.: Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005; 22: 795–801. CrossRef MEDLINE |
| 11. | Gonzalez-Perez A, Saez ME, Johansson S, et al.: Risk factors associated with uncomplicated peptic ulcer and changes in medication use after diagnosis. PLoS One 2014; 9: e101768. CrossRef MEDLINE PubMed Central |
| 12. | Fischbach W, Bornschein J, Hoffmann JC, et al.: Aktualisierte S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Juli 2022 – AWMF-Registernummer: 021 – 001. https://register.awmf.org/assets/guidelines/021-001l_S2k_Helicobacter-pylori-gastroduodenale-Ulkuskrankheit_2022-07_1.pdf (last accessed 13 April 2023). |
| 13. | Kelly JP, Kaufman DW, Jurgelon JM, et al.: Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348 (9039): 1413–16. CrossRef MEDLINE |
| 14. | Hernandez-Diaz S, Rodriguez LA: Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093–99. CrossRef MEDLINE |
| 15. | Crooks CJ, West J, Card TR: Comorbidities affect risk of nonvariceal upper gastrointestinal bleeding. Gastroenterology 2013; 144: 1384–93. CrossRef MEDLINE PubMed Central |
| 16. | Weil J, Langman MJ, Wainwright P, et al.: Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000; 46: 27–31. CrossRef MEDLINE PubMed Central |
| 17. | Gutthann SP, Garcia Rodriguez LA, Raiford DS: Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997; 8: 18–24. CrossRef MEDLINE |
| 18. | Fischbach W: Medikamenteninduzierte gastrointestinale Blutung. Internist. 2019; 60: 597–607. CrossRef MEDLINE |
| 19. | Jarupongprapa S, Ussavasodhi P, Katchamart W: Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis. J Gastroenterol 2013; 48: 830–38. CrossRef MEDLINE |
| 20. | Rostom A, Muir K, Dube C, et al.: Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug Healthc Patient Saf 2009; 1: 47–71. CrossRef MEDLINE PubMed Central |
| 21. | Scally B, Emberson JR, Spata E, et al.: Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol 2018; 3: 231–41. CrossRef MEDLINE |
| 22. | Wang X, Tian HJ, Yang HK, et al.: Meta-analysis: Cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis. Eur J Gastroenterol Hepatol 2011; 23: 876–80. CrossRef MEDLINE |
| 23. | Rane PP, Guha S, Chatterjee S, et al.: Prevalence and predictors of non-evidence based proton pump inhibitor use among elderly nursing home residents in the US. Res Social Adm Pharm 2017; 13: 358–63. CrossRef MEDLINE |
| 24. | Hoffmann F, Glaeske G, Schmiemann G: Steigende Verordnungszahlen von Protonenpumpenhemmern im ambulant-ärztlichen Bereich über die Jahre 2005-2013. Z Gastroenterol 2015; 53: 95–100. CrossRef MEDLINE |
| 25. | Haastrup PF, Thompson W, Søndergaard J, et al.: Side Effects of Long-Term Proton Pump Inhibitor Use: A Review. Basic Clin Pharmacol Toxicol 2018; 123: 114–21. CrossRef MEDLINE |
| 26. | Targownik LE, Fisher DA, Saini SD. AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review. Gastroenterology 2022; 162: 1334–42. CrossRef MEDLINE |
| 27. | Beschluss der Bundesärztekammer über die Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten, Gesamtnovelle 2020. Dtsch Arztebl 2020; 117 (40): A-1883/B-1603. VOLLTEXT |
| 28. | Carson JL, Sieber F, Cook DR, et al.: Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial. Lancet 2015; 385 (9974): 1183–89. CrossRef MEDLINE |
| 29. | Carson JL, Stanworth SJ, Denis JA, et al.: Transfusion thresholds for guiding red blood cell transfusion. Cochrane Database Syst Rev 2021; 12 (12): CD002042 CrossRef MEDLINE PubMed Central |
| 30. | Berger MD, Gerber B, Arn K, et al.: Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation. Haematologica 2012; 97: 116–22. CrossRef MEDLINE PubMed Central |
| 31. | Leahy MF, Trentino KM, May C, et al.: Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system-wide patient blood management program. Transfusion 2017; 57: 2189–96. CrossRef MEDLINE |
| 32. | Amano K, Baracos VE, Hopkinson JB: Integration of palliative, supportive, and nutritional care to alleviate eating-related distress among advanced cancer patients with cachexia and their family members. Crit Rev in Oncol Hematol 2019; 143: 117–23. CrossRef MEDLINE |
| 33. | Tobberup R, Thoresen L, Falkmer UG, et al.: Effects of current parenteral nutrition treatment on health-related quality of life, physical function nutritional status, survival and adverse events exclusively in patients with advanced cancer: A systematic literature review. Crit Rev Oncol Hematol 2019; 139: 96–107. CrossRef MEDLINE |
| 34. | Arends J, Strasser F, Gonella S, et al.: Cancer cachexia in adult patients: ESMO Clinical Practice. ESMO Open 2021; 6 (3): 100092. CrossRef MEDLINE PubMed Central |
| 35. | Orrevall Y: Nutritional support at the end of life. Nutrition 2015; 31: 615–6. CrossRef MEDLINE |
| 36. | Arends J, Bachmann P, Bracos V, et al.: ESPEN guidelines on nutrition in cancer patients. Clin Nutr 2017; 36: 11–48 CrossRef MEDLINE |
| 37. | Arends J, Jordan K: Supplemental parenteral nutrition: decisions based on weak evidence. ESMO Open 2020; 5 (4): e000831. CrossRef MEDLINE PubMed Central |
| 38. | Raijmakers NJH, van Zuylen L, Costantini M, et al.: Artificial nutrition and hydration in the last week of life in cancer patients. A systematic literature review of practices and effects. Ann Oncol 2022; 22: 1478–86. CrossRef MEDLINE |
| 39. | Bouleuc C, Anota A, Cornet C, et al.: Impact on Health-related Quality of Life of Parenteral Nutrition for Patients with Advanced Cancer Cachexia: results from a Randomized Controlled Trial. Oncologist 2020; 25: e843–51. CrossRef MEDLINE PubMed Central |
| 40. | McCann RM, Hall WJ, Groth-Juncker A: Comfort care for terminally ill patients. The appropriate use of nutrition and hydration. JAMA 1994; 272: 1263–6. CrossRef MEDLINE |
| 41. | Chow R, Bruera E, Arends J, et al.: Enteral and parenteral nutrition in cancer patients a comparison of complication rates: an updated systematic review and (cumulative) meta-analysis. Support Care Cancer 2020; 28: 979–1010. CrossRef MEDLINE |
| 42. | Collet J-P, Thiele H, Barbato E, et al.: 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021; 42: 1289–367 CrossRef MEDLINE |
| 43. | Thiele H, Bauersachs J, Mehilli J, et al.: Kommentar zu den 2020er-Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zum Management des akuten Koronarsyndroms bei Patienten ohne persistierende ST-Strecken-Hebung. Kardiologe 2021; 15: 19–31. CrossRef |
| 44. | Hindricks G, Potpara T, Dagres N, et al.: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC); Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42: 373–498 CrossRef MEDLINE |
| 45. | Rourke EJ: Ten Years of Choosing Wisely to Reduce Low-Value Care. New Engl J Med 2022; 386 (14): 1293–5. CrossRef MEDLINE |
Keine Nachrichten verfügbar.
Literaturnachweise
-
1. Klug entscheiden – Eine Initiative der Deutschen Gesellschaft für Innere Medizin (DGIM). Deutsches Ärzteblatt 2021; 118: Sammelband April 2021. https://www.klug-entscheiden.com/fileadmin/user_upload/2021_Sammelband_Klug_entscheiden_Web_final.pdf (last accessed 13 April 2023). 2. https://dgim.de/veroeffentlichungen/klug-entscheiden/ (last accessed 13 April 2023). 3. Singh P, Arora A, Strand TA, et al.: Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2018; 16: 823–36 CrossRef MEDLINE 4. Palmieri B, Vadala M, Laurino C: Gluten-free diet in non-celiac patients: beliefs, truths, advantages and disadvantages. Minerva Gastroenterol Dietol 2019; 65: 153–62. CrossRef MEDLINE 5. Melini V, Melini F: Gluten-Free Diet: Gaps and Needs for a Healthier Diet. Nutrients 2019; 11: 170. CrossRef MEDLINE PubMed Central 6. Leonard MM, Sapone A, Catassi C, et al.: Celiac Disease and Nonceliac Gluten Sensitivity: A Review. JAMA 2017; 318: 647–56. CrossRef MEDLINE 7. Welstead L: The Gluten-Free Diet in the 3rd Millennium: Rules, Risks and Opportunities. Diseases 2015; 3: 136–49. CrossRef MEDLINE PubMed Central 8. Felber J, Bläker H, Fischbach W, et al.: Aktualisierte S2k-Leitlinie Zöliakie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol 2022; 60: 790–856. CrossRef MEDLINE 9. Castellsague J, Riera-Guardia N, Calingaert B, et al.: Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012; 35: 1127–46. CrossRef MEDLINE PubMed Central 10. Yeomans ND, Lanas AI, Talley NJ, et al.: Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005; 22: 795–801. CrossRef MEDLINE 11. Gonzalez-Perez A, Saez ME, Johansson S, et al.: Risk factors associated with uncomplicated peptic ulcer and changes in medication use after diagnosis. PLoS One 2014; 9: e101768. CrossRef MEDLINE PubMed Central 12. Fischbach W, Bornschein J, Hoffmann JC, et al.: Aktualisierte S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Juli 2022 – AWMF-Registernummer: 021 – 001. https://register.awmf.org/assets/guidelines/021-001l_S2k_Helicobacter-pylori-gastroduodenale-Ulkuskrankheit_2022-07_1.pdf (last accessed 13 April 2023). 13. Kelly JP, Kaufman DW, Jurgelon JM, et al.: Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348 (9039): 1413–16. CrossRef MEDLINE 14. Hernandez-Diaz S, Rodriguez LA: Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093–99. CrossRef MEDLINE 15. Crooks CJ, West J, Card TR: Comorbidities affect risk of nonvariceal upper gastrointestinal bleeding. Gastroenterology 2013; 144: 1384–93. CrossRef MEDLINE PubMed Central 16. Weil J, Langman MJ, Wainwright P, et al.: Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000; 46: 27–31. CrossRef MEDLINE PubMed Central 17. Gutthann SP, Garcia Rodriguez LA, Raiford DS: Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997; 8: 18–24. CrossRef MEDLINE 18. Fischbach W: Medikamenteninduzierte gastrointestinale Blutung. Internist. 2019; 60: 597–607. CrossRef MEDLINE 19. Jarupongprapa S, Ussavasodhi P, Katchamart W: Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis. J Gastroenterol 2013; 48: 830–38. CrossRef MEDLINE 20. Rostom A, Muir K, Dube C, et al.: Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug Healthc Patient Saf 2009; 1: 47–71. CrossRef MEDLINE PubMed Central 21. Scally B, Emberson JR, Spata E, et al.: Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol 2018; 3: 231–41. CrossRef MEDLINE 22. Wang X, Tian HJ, Yang HK, et al.: Meta-analysis: Cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis. Eur J Gastroenterol Hepatol 2011; 23: 876–80. CrossRef MEDLINE 23. Rane PP, Guha S, Chatterjee S, et al.: Prevalence and predictors of non-evidence based proton pump inhibitor use among elderly nursing home residents in the US. Res Social Adm Pharm 2017; 13: 358–63. CrossRef MEDLINE 24. Hoffmann F, Glaeske G, Schmiemann G: Steigende Verordnungszahlen von Protonenpumpenhemmern im ambulant-ärztlichen Bereich über die Jahre 2005-2013. Z Gastroenterol 2015; 53: 95–100. CrossRef MEDLINE 25. Haastrup PF, Thompson W, Søndergaard J, et al.: Side Effects of Long-Term Proton Pump Inhibitor Use: A Review. Basic Clin Pharmacol Toxicol 2018; 123: 114–21. CrossRef MEDLINE 26. Targownik LE, Fisher DA, Saini SD. AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review. Gastroenterology 2022; 162: 1334–42. CrossRef MEDLINE 27. Beschluss der Bundesärztekammer über die Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten, Gesamtnovelle 2020. Dtsch Arztebl 2020; 117 (40): A-1883/B-1603. VOLLTEXT 28. Carson JL, Sieber F, Cook DR, et al.: Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial. Lancet 2015; 385 (9974): 1183–89. CrossRef MEDLINE 29. Carson JL, Stanworth SJ, Denis JA, et al.: Transfusion thresholds for guiding red blood cell transfusion. Cochrane Database Syst Rev 2021; 12 (12): CD002042 CrossRef MEDLINE PubMed Central 30. Berger MD, Gerber B, Arn K, et al.: Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation. Haematologica 2012; 97: 116–22. CrossRef MEDLINE PubMed Central 31. Leahy MF, Trentino KM, May C, et al.: Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system-wide patient blood management program. Transfusion 2017; 57: 2189–96. CrossRef MEDLINE 32. Amano K, Baracos VE, Hopkinson JB: Integration of palliative, supportive, and nutritional care to alleviate eating-related distress among advanced cancer patients with cachexia and their family members. Crit Rev in Oncol Hematol 2019; 143: 117–23. CrossRef MEDLINE 33. Tobberup R, Thoresen L, Falkmer UG, et al.: Effects of current parenteral nutrition treatment on health-related quality of life, physical function nutritional status, survival and adverse events exclusively in patients with advanced cancer: A systematic literature review. Crit Rev Oncol Hematol 2019; 139: 96–107. CrossRef MEDLINE 34. Arends J, Strasser F, Gonella S, et al.: Cancer cachexia in adult patients: ESMO Clinical Practice. ESMO Open 2021; 6 (3): 100092. CrossRef MEDLINE PubMed Central 35. Orrevall Y: Nutritional support at the end of life. Nutrition 2015; 31: 615–6. CrossRef MEDLINE 36. Arends J, Bachmann P, Bracos V, et al.: ESPEN guidelines on nutrition in cancer patients. Clin Nutr 2017; 36: 11–48 CrossRef MEDLINE 37. Arends J, Jordan K: Supplemental parenteral nutrition: decisions based on weak evidence. ESMO Open 2020; 5 (4): e000831. CrossRef MEDLINE PubMed Central 38. Raijmakers NJH, van Zuylen L, Costantini M, et al.: Artificial nutrition and hydration in the last week of life in cancer patients. A systematic literature review of practices and effects. Ann Oncol 2022; 22: 1478–86. CrossRef MEDLINE 39. Bouleuc C, Anota A, Cornet C, et al.: Impact on Health-related Quality of Life of Parenteral Nutrition for Patients with Advanced Cancer Cachexia: results from a Randomized Controlled Trial. Oncologist 2020; 25: e843–51. CrossRef MEDLINE PubMed Central 40. McCann RM, Hall WJ, Groth-Juncker A: Comfort care for terminally ill patients. The appropriate use of nutrition and hydration. JAMA 1994; 272: 1263–6. CrossRef MEDLINE 41. Chow R, Bruera E, Arends J, et al.: Enteral and parenteral nutrition in cancer patients a comparison of complication rates: an updated systematic review and (cumulative) meta-analysis. Support Care Cancer 2020; 28: 979–1010. CrossRef MEDLINE 42. Collet J-P, Thiele H, Barbato E, et al.: 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021; 42: 1289–367 CrossRef MEDLINE 43. Thiele H, Bauersachs J, Mehilli J, et al.: Kommentar zu den 2020er-Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zum Management des akuten Koronarsyndroms bei Patienten ohne persistierende ST-Strecken-Hebung. Kardiologe 2021; 15: 19–31. CrossRef 44. Hindricks G, Potpara T, Dagres N, et al.: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC); Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42: 373–498 CrossRef MEDLINE 45. Rourke EJ: Ten Years of Choosing Wisely to Reduce Low-Value Care. New Engl J Med 2022; 386 (14): 1293–5. CrossRef MEDLINE